Medications for Neurotrophic Keratitis
About Neurotrophic Keratitis
Neurotrophic keratitis (NK) is a rare disease of the corneal epithelium which is characterized by epithelium breakdown, reduced healing, ulceration and perforation of the cornea. This occurs when there is damage to the trigeminal nerve (cranial nerve V) or its branches. Damage to the nerve can be caused by ocular and systemic diseases, physical damage or infections.
The cornea is a clear layer that covers the front portion of the eye and does not contain any blood vessels, as blood vessels would block vision. Blood vessels usually supply tissues with substances that are required for maintaining good tissue health. As the cornea has no blood vessels the trigeminal nerves take over this role in supplying essential substances to maintain the integrity and function of the cornea. Any deficiency of the corneal trigeminal innervation leads to metabolic disturbances of the cornea and also reduced repair and maintenance of the corneal structure. This causes recurrent or persistent corneal defects and at later stages of NK may progress to corneal ulcer, corneal stromal melting or corneal perforation.
Symptoms of NK are usually visual changes due to the corneal epithelial defects, scarring and swelling. Patients do not usually complain of any eye discomfort or pain as there is a lack of corneal sensation due to damage to the trigeminal nerves.
Drugs used to treat Neurotrophic Keratitis
The following list of medications are in some way related to, or used in the treatment of this condition.
Learn more about Neurotrophic Keratitis
IBM Watson Micromedex
|Rating||For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|
|Activity||Activity is based on recent site visitor activity relative to other medications in the list.|
|OTC||Over the Counter.|
|Rx/OTC||Prescription or Over the Counter.|
|Off-label||This medication may not be approved by the FDA for the treatment of this condition.|
|A||Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).|
|B||Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.|
|C||Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.|
|D||There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.|
|X||Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.|
|N||FDA has not classified the drug.|
|Controlled Substances Act (CSA) Schedule|
|N||Is not subject to the Controlled Substances Act.|
|1||Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.|
|2||Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.|
|3||Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.|
|4||Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.|
|5||Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.|
|X||Interacts with Alcohol.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.